Botanical Therapeutics for Parkinson's Disease

被引:1
|
作者
Li, Wen-wei [1 ,2 ,3 ]
机构
[1] Fudan Univ, Dept Neurol, Shanghai Publ Hlth Clin Ctr, Shanghai 201500, Peoples R China
[2] Fudan Univ, Zhongshan Hosp South Branch, Dept Neurol, Shanghai 201500, Peoples R China
[3] Fudan Univ, Inst Integrat Med, Inst Neurol, Shanghai 201500, Peoples R China
基金
中国国家自然科学基金;
关键词
Parkinson's disease; botanical therapeutics; Chinese medicine; neurotrophic activity; protein aggregation; neuroinflammation; TRADITIONAL CHINESE MEDICINE; CLINICAL DIAGNOSTIC-CRITERIA; ALPHA-SYNUCLEIN; WITHANIA-SOMNIFERA; MUCUNA-PRURIENS; DOUBLE-BLIND; AUTOPHAGY; DOPAMINE; CLEARANCE; MICROGLIA;
D O I
10.1007/s11655-020-3096-5
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Parkinson's disease (PD) was first formally described by James Parkinson in 1817, but the shaking of limbs was described in the literature of several ancient civilizations, such as ancient Chinese civilization and ancient Indian civilization. Historically, botanical drugs were used as the main source for the treatment of such kind of disorders. In Western countries, plant extracts also occupied an important place in the earlier medications of PD. With the adventure of synthetic drugs, the role of plant-derived drugs in management of PD has been diminished. Nowadays, there is still no cure for PD, dopaminergic (DA) medication is the treatment of choice, which is just designed to ameliorate symptoms of PD, and long-term use of DA medication will result in reduced efficacy and severe adverse reactions. It is necessary to explore new methods for the treatment of PD. Chinese medicine (CM) developed a holistic and unique theoretical system, and botanical drugs are widely used in practice for more than two millennia. Modern pharmacological studies have proved that Chinese herbs have potential therapeutic effects on PD, such as enhancing neurotrophic activity, clearing protein aggregates, regulating neuroinflammation, etc. All the advances provide us with hope for developing CM as a mainstream medication for treating PD.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 50 条
  • [21] Norepinephrine: the next therapeutics frontier for Parkinson's disease
    LeWitt P.A.
    Translational Neurodegeneration, 1 (1)
  • [22] Levodopa therapeutics for Parkinson's disease: new developments
    LeWitt, Peter A.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S31 - S34
  • [23] Glunomab: a novel therapeutics for the treatment of Parkinson's Disease
    Torrente, D.
    Su, E.
    Schielke, G. P.
    Warnock, M.
    Stevenson, T.
    Mann, K.
    Lesept, F.
    Deletage, N.
    Blanc, M.
    Vivien, D.
    Lawrence, D.
    MOVEMENT DISORDERS, 2023, 38 : S595 - S595
  • [24] Animal Models of Parkinson's Disease: A Gateway to Therapeutics?
    Le, Weidong
    Sayana, Pavani
    Jankovic, Joseph
    NEUROTHERAPEUTICS, 2014, 11 (01) : 92 - 110
  • [25] Cell-based Therapeutics for Parkinson's Disease
    Sanchez-Pernaute, Rosario
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 9 - 10
  • [26] Nucleic Acid–Based Therapeutics for Parkinson’s Disease
    Masayuki Nakamori
    Eunsung Junn
    Hideki Mochizuki
    M. Maral Mouradian
    Neurotherapeutics, 2019, 16 : 287 - 298
  • [27] Microbiome-based therapeutics for Parkinson's disease
    Hamilton, Adam M.
    Krout, Ian N.
    White, Alexandria C.
    Sampson, Timothy R.
    NEUROTHERAPEUTICS, 2024, 21 (06)
  • [28] Old and new challenges in Parkinson's disease therapeutics
    Pires, Ana O.
    Teixeira, F. G.
    Mendes-Pinheiro, B.
    Serra, Sofia C.
    Sousa, Nuno
    Salgado, Antonio J.
    PROGRESS IN NEUROBIOLOGY, 2017, 156 : 69 - 89
  • [29] Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?
    Weidong Le
    Pavani Sayana
    Joseph Jankovic
    Neurotherapeutics, 2014, 11 : 92 - 110
  • [30] Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease
    Francardo, Veronica
    Schmitz, Yvonne
    Sulzer, David
    Cenci, M. Angela
    EXPERIMENTAL NEUROLOGY, 2017, 298 : 137 - 147